Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
Shintaro Narita, Takahiro Kimura, Shingo Hatakeyama, Kenichi Hata, Takafumi Yanagisawa, Shinya Maita, Shuji Chiba, Hiromi Sato, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, K. Takayama, Katsumi Okane, Toshiya Ishida, Yohei Horikawa, Teruaki Kumazawa, Jiro Shimoda, Takehiro Suzuki, Chikara Οhyama, Shin Egawa, Tomonori Habuchi
Topics & Concepts
MedicineAbiraterone acetateProstate cancerHazard ratioDocetaxelInternal medicineOncologyPropensity score matchingAndrogen deprivation therapyProgression-free survivalConfidence intervalOverall survivalCancerProstate Cancer Treatment and ResearchBone health and treatmentsProstate Cancer Diagnosis and Treatment